The German Company Wants to Keep Prostate Cancer Drug Xofigo to Itself

Germany's Bayer wants to keep Xofigo, a first-of-its-kind prostate cancer treatment, all to itself. It co-promotes the drug in the U.S. with Norwegian biotech Algeta, which Tuesday said Bayer had made a preliminary takeover approach valuing the company at about $2.4 billion.